Lansoprazol Sandoz (Lansoprazole)

Lansoprazol Sandoz is a proton pump inhibitor that lowers gastric acidity in several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation.
• Erosive esophagitis: promotes healing of inflamed esophageal tissue.
• Peptic ulcer disease: supports ulcer healing and prevents recurrence.
• Helicobacter pylori eradication: used as part of combination therapy to eliminate the bacteria.

• Lansoprazole irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, thereby increasing gastric pH and allowing mucosal healing in acid‑related conditions.

Lansoprazol Sandoz may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: loose stools, usually self‑limiting.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased gas production.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent diarrhea with abdominal pain.
• Low magnesium levels: muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: abnormal liver function tests.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Before prescribing Lansoprazol Sandoz, clinicians should consider several safety aspects.

• Assess renal function: adjust use in severe impairment.
• Evaluate hepatic status: monitor in patients with liver disease.
• Review concomitant medications: potential for drug interactions.
• Long‑term therapy: consider risk of bone fracture and vitamin B12 deficiency.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lansoprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid)

• Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption, may lose efficacy.
• Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability.
• Clopidogrel: reduced activation, potentially lowering antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, monitor coagulation.
• Digoxin: increased serum levels, watch for toxicity.
• Methotrexate (high dose): decreased clearance, monitor renal function.
• Diazepam: increased sedation, adjust dose if needed.